登录 | 注册    关注公众号  
搜索

LIGHT信息

英文名称:Tumor necrosis factor superfamily member 14
中文名称:肿瘤坏死因子超家族成员14
靶点别称:CD258 Antigen,Herpes Virus Entry Mediator Ligand,TNFSF14,Herpesvirus Entry Mediator Ligand,LIGHT,Tumor Necrosis Factor (Ligand) Superfamily, Member 14,CD258,HVEM-L,Tumor Necrosis Factor Ligand 1D,LTg,HVEML,TNF Superfamily Member 14,Tumor Necrosis Factor Ligand Superfamily Member 14,Tumor Necrosis Factor Superfamily Member 14
上市药物数量:0
临床药物数量:1
最高研发阶段:临床一期

LIGHT 分子别名

CD258 antigen,CD258,HVEM-L,LIGHT,LTg,TNFSF14,TR2,HVEML

LIGHT 分子背景

Tumor necrosis factor ligand superfamily member 14(LIGHT) is a tumor necrosis factor (TNF) superfamily ligand that regulates T cell immune responses by signaling through the herpes virus entry mediator (HVEM) and the lymphotoxin beta receptor (LTbetaR). LIGHT has emerged as a potent initiator of T cell co-stimulation signals effecting CTL-mediated tumor rejection, allograft rejection and graft versus host disease. Constitutive expression of LIGHT leads to tissue destruction and autoimmune-like disease syndromes.

LIGHT 前沿进展

LIGHT临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Quisovalimab CERC-002; AEVI-002; MDGN-002; SAR-252067; AVTX-002 La Jolla Pharmaceutical Company, 协和发酵麒麟株式会社 详情
CBS-001 CBS-001 临床一期 Centessa Pharmaceuticals Plc 特发性肺纤维化, 炎性疾病 详情

消息提示

请输入您的联系方式,再点击提交!

确定